Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Vistagen to Present at Stifel 2023 Healthcare Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 ? 15, 2023 at the Lotte New York Palace Hotel in New York City.

Stifel 2023 Healthcare Conference

A webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative.

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen's pipeline contains six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug of an antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines are neuroactive nasal sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression, and several other CNS disorders. Connect at www.Vistagen.com.


These press releases may also interest you

at 09:35
Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide...

at 09:30
The Prime Minister, Justin Trudeau, today issued the following statement on National Nursing Week, which runs from May 6 to 12: "Today, as we mark the start of National Nursing week, I join Canadians across the country to celebrate our nurses, their...

at 09:30
CG Pharmaceuticals, a late-stage clinical biopharmaceutical company specializing in metastatic pancreatic ductal adenocarcinoma (PDAC) maintenance therapy (NCT05249101), will feature one of our investigators, Dr. Christos Fountzilas from Roswell Park...

at 09:25
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides an update on the initiative to...

at 09:23
To mark mental health awareness, OOt Social Health proudly launches its app to revolutionise community engagement. OOt Social Health represents a paradigm shift in fostering vibrant communities through face-to-face interactions, blending proximity,...

at 09:21
Scinai Immunotherapeutics Ltd. , a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it had had...



News published on and distributed by: